Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507867 | 1.00 | BTK (0.54) | BTKUSP30GPR119IDO1TDO2 | |
| SCHEMBL14925900 | 0.91 | BTK (0.46) | BTKUSP30GPR119IDO1TDO2 | |
| SCHEMBL29742073 | 0.89 | BTK (0.45) | BTKGPR119IDO1TDO2 | |
| SCHEMBL14912698 | 0.89 | BTK (0.45) | BTKGPR119IDO1TDO2 | |
| SCHEMBL14915914 | 0.89 | BTK (0.45) | BTKGPR119IDO1TDO2 | |
| SCHEMBL10256545 | 0.88 | BTK (0.44) | BTKUSP30GPR119IDO1TDO2 | |
| SCHEMBL25180233 | 0.87 | BTK (0.42) | BTKCCND1 | |
| SCHEMBL29230409 | 0.87 | BTK (0.42) | BTKCCND1 | |
| SCHEMBL29230406 | 0.87 | BTK (0.42) | BTKCCND1 | |
| SCHEMBL25525222 | 0.87 | BTK (0.45) | BTKUSP30IDO1TDO2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-11-30 | — | — | US | disclosed |
| CN-116568687-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4214206-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-20 | — | — | US | disclosed |
| WO-2022057894-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382916-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP3A7 | BTK 1247/4885USP30 3965/4885GPR119 2684/4885 |
| US-12173008-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, ABL1 | BTK 1/4885USP30 2182/4885GPR119 2806/4885 |
| US-11655254-B2 | Substituted piperazines as BTK inhibitors | BTK, SYK, LYN | BTK 1/4885USP30 2357/4885GPR119 3028/4885 |
| US-20220332719-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | BTK, SYK, LYN | BTK 1/4885USP30 3367/4885GPR119 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.